Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

The Clinical Potential of Ademetionine (S-Adenosylmethionine) in Neurological Disorders

The Clinical Potential of Ademetionine (S-Adenosylmethionine) in Neurological Disorders This review focuses on the biochemical and clinical aspects of methylation in neuropsychiatrie disorders and the clinical potential of their treatment with ademetionine (S-adenosylmethionine; SAMe). SAMe is required in numerous transmethylation reactions involving nucleic acids, proteins, phospholipids, amines and other neurotransmitters. The synthesis of SAMe is intimately linked with folate and vitamin B12 (cyanocobalamin) metabolism, and deficiencies of both these vitamins have been found to reduce CNS SAMe concentrations. Both folate and vitamin B12 deficiency may cause similar neurological and psychiatric disturbances including depression, dementia, myelopathy and peripheral neuropathy. SAMe has a variety of pharmacological effects in the CNS, especially on monoamine neurotransmitter metabolism and receptor systems. SAMe has antidepressant properties, and preliminary studies indicate that it may improve cognitive function in patients with dementia. Treatment with methyl donors (betaine, methionine and SAMe) is associated with remyelination in patients with inborn errors of folate and C-l (one-carbon) metabolism. These studies support a current theory that impaired methylation may occur by different mechanisms in several neurological and psychiatric disorders. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Drugs Springer Journals

The Clinical Potential of Ademetionine (S-Adenosylmethionine) in Neurological Disorders

Drugs , Volume 48 (2) – Dec 11, 2012

Loading next page...
 
/lp/springer-journals/the-clinical-potential-of-ademetionine-s-adenosylmethionine-in-Gk0OyvoWQr

References (143)

Publisher
Springer Journals
Copyright
Copyright
Subject
Medicine & Public Health; Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine
ISSN
0012-6667
eISSN
1179-1950
DOI
10.2165/00003495-199448020-00002
Publisher site
See Article on Publisher Site

Abstract

This review focuses on the biochemical and clinical aspects of methylation in neuropsychiatrie disorders and the clinical potential of their treatment with ademetionine (S-adenosylmethionine; SAMe). SAMe is required in numerous transmethylation reactions involving nucleic acids, proteins, phospholipids, amines and other neurotransmitters. The synthesis of SAMe is intimately linked with folate and vitamin B12 (cyanocobalamin) metabolism, and deficiencies of both these vitamins have been found to reduce CNS SAMe concentrations. Both folate and vitamin B12 deficiency may cause similar neurological and psychiatric disturbances including depression, dementia, myelopathy and peripheral neuropathy. SAMe has a variety of pharmacological effects in the CNS, especially on monoamine neurotransmitter metabolism and receptor systems. SAMe has antidepressant properties, and preliminary studies indicate that it may improve cognitive function in patients with dementia. Treatment with methyl donors (betaine, methionine and SAMe) is associated with remyelination in patients with inborn errors of folate and C-l (one-carbon) metabolism. These studies support a current theory that impaired methylation may occur by different mechanisms in several neurological and psychiatric disorders.

Journal

DrugsSpringer Journals

Published: Dec 11, 2012

There are no references for this article.